Background
Methods
Study design
Imaging assessments
Modified RECIST 1.1[13] | Modified EORTC [12] | ICDS [14] | |
---|---|---|---|
CR | Disappearance of all target lesions; all target lymph nodes are < 10 mm in the short axis | Complete resolution of abnormal 18FDG uptake within the tumor volume of all target lesions to a level that is indistinguishable from surrounding normal tissue | Disappearance of all disease |
PR | At least a 30% decrease in SLD using baseline SLD as a reference | Reduction of the sum of the SUVmax by ≥ 15–25% after 1 cycle and a decrease of ≥ 25% compared with baseline after > 1 treatment cycle | A decrease in size (%Δ Choi SLD) ≥ 10% or an increase in CT density > 15% compared with baseline, no new lesions, and no obvious progression of nonmeasurable disease |
SD | Neither sufficient shrinkage of target lesions to qualify for PR nor sufficient increase to qualify for PD, taking as reference the nadir SLD | %ΔΣ SUVmax increased by < 25% or decreased by < 15% compared with baseline and no visible extent of 18FDG tumor uptake (> 20% in the longest dimension) | Does not meet the criteria for CR, PR, or PD; no symptomatic deterioration attributed to tumor progression |
PD | At least a 20% increase in the SLD of target lesions, taking as reference the nadir SLD; in addition to the relative increase of 20% in SLD, the SLD must also demonstrate an absolute increase of ≥ 5 mm | %ΔΣ SUVmax increased by ≥ 25% compared with baseline scan, visible increase in the extent of 18FDG uptake (> 20% in the longest dimension) or the appearance of new 18FDG uptake in metastatic lesions | An increase in unidimensional tumor size (Choi SLD) ≥ 10% and does not meet the criteria for PR using CT density; any new lesions identified by CT/MRI; new intratumoral nodules or increase in the size of existing intratumoral nodules |
UE | A target lesion present at baseline that subsequently became UE | 18FDG-PET exam was unavailable or deemed UE;a response will be UE unless unequivocal PD is determined on the basis of the evaluable target lesion | The CT/MRI exam is unavailable or deemed UE; if a target lesion is deemed UE by density and size measurement and the rules for PD do not apply, a response of CR, PR, or SD cannot be assigned for the time point and the response will be UE |
Statistics
Results
Patients
Overall (N = 190) | |
---|---|
Sex, n (%) | |
Female | 105 (55) |
Male | 85 (45) |
Age, median (Q1, Q3), years | 33 (26, 43) |
ECOG performance statusa, n (%) | |
0 | 106 (56) |
1 | 76 (40) |
2 | 6 (3) |
Previous treatment | |
Resection/surgery | 132 (70) |
Bisphosphonates | 38 (20) |
Radiotherapy | 37 (20) |
Chemotherapy | 21 (11) |
GCTB disease type, n (%) | |
Recurrent unresectable | 92 (48) |
Primary unresectable | 43 (23) |
Recurrent resectable | 29 (15) |
Primary resectable | 26 (14) |
Location of target lesionb, n (%) | |
Pelvis/sacrum | 61 (32) |
Lower extremities | 39 (21) |
Lung | 38 (20) |
Spine | 18 (10) |
Upper extremities | 17 (9) |
Otherc | 11 (6) |
Skull/neck | 5 (3) |
Missing | 1 (1) |
Overall best response | RECIST 1.1 | EORTC | ICDS | |
---|---|---|---|---|
Proportion of responders, n/N (%) | ||||
Overall | 136/190 (71.6) | 47/187 (25.1) | 25/26 (96.2) | 134/176 (76.1) |
Study 1 | 20/27 (74.1) | 3/27 (11.1) | 15/16 (93.8) | 18/23 (78.3) |
Study 2 | 116/163 (71.2) | 44/160 (27.5) | 10/10 (100.0) | 116/153 (75.8) |
Cohort 1 | 76/114 (66.7) | 36/113 (31.9) | 4/4 (100.0) | 76/105 (72.4) |
Cohort 2 | 40/49 (81.6) | 8/47 (17.0) | 6/6 (100.0) | 40/48 (83.3) |
Median time to first OTR, months (95% CI)b | 3.1 (2.89–3.65) | NE (20.9–NE) | 2.7 (1.64–2.79) | 3.0 (2.79–3.48) |
Patients with sustained OTR, n/N (%) | ||||
Overall | ||||
≥ 4 weeks | 102/153 (66.7) | 32/150 (21.3) | 18/20 (90.0) | 101/143 (70.6) |
≥ 12 weeks | 98/144 (68.1) | 32/141 (22.7) | 16/17 (94.1) | 97/135 (71.9) |
≥ 24 weeks | 76/111 (68.5) | 26/109 (23.9) | 11/12 (91.7) | 76/102 (74.5) |
Study 1 | ||||
≥ 4 weeks | 15/24 (62.5) | 2/24 (8.3) | 11/13 (84.6) | 13/20 (65.0) |
≥ 12 weeks | 14/20 (70.0) | 2/20 (10.0) | 10/11 (90.9) | 13/17 (76.5) |
≥ 24 weeks | 12/17 (70.6) | 2/17 (11.8) | 8/9 (88.9) | 12/14 (85.7) |
Study 2 | ||||
≥ 4 weeks | 87/129 (67.4) | 30/126 (23.8) | 7/7 (100.0) | 88/123 (71.5) |
≥ 12 weeks | 84/124 (67.7) | 30/121 (24.8) | 6/6 (100.0) | 84/118 (71.2) |
≥ 24 weeks | 64/94 (68.1) | 24/92 (26.1) | 3/3 (100.0) | 64/88 (72.7) |
Cohort 1 | ||||
≥ 4 weeks | 59/91 (64.8) | 25/90 (27.8) | 3/3 (100.0) | 60/85 (70.6) |
≥ 12 weeks | 56/87 (64.4) | 25/86 (29.1) | 3/3 (100.0) | 57/81 (70.4) |
≥ 24 weeks | 49/73 (67.1) | 22/73 (30.1) | 2/2 (100.0) | 50/67 (74.6) |
Cohort 2 | ||||
≥ 4 weeks | 28/38 (73.7) | 5/36 (13.9) | 4/4 (100.0) | 28/38 (73.7) |
≥ 12 weeks | 28/37 (75.7) | 5/35 (14.3) | 3/3 (100.0) | 27/37 (73.0) |
≥ 24 weeks | 15/21 (71.4) | 2/19 (10.5) | 1/1 (100.0) | 14/21 (66.7) |
Patients with tumor controlc, % | ||||
≥ 4 weeks | 148/153 (96.7) | 145/150 (96.7) | 19/20 (95.0) | 139/143 (97.2) |
≥ 12 weeks | 139/144 (96.5) | 137/141 (97.2) | 17/17 (100.0) | 131/135 (97.0) |
≥ 24 weeks | 109/111 (98.2) | 108/109 (99.1) | 12/12 (100.0) | 101/102 (99.0) |
n
| Mean | SD | Min | Q1 | Median | Q3 | Max | |
---|---|---|---|---|---|---|---|---|
LD, mm | 174 | 68.4 | 40.8 | 10.0 | 38.0 | 62.5 | 91.0 | 283.0 |
SUVmax | 26 | 11.1 | 4.7 | 3.8 | 7.9 | 10.6 | 13.6 | 21.6 |